MyoKardia Shares Skyrocket On Promising Phase II Data In HCM

Biotech hopes to accelerate clinical development plans for mavacamten after study meets several endpoints in obstructive hypertrophic cardiomyopathy, an unmet medical need.

Anatomy of Human Heart

It was only 10 patients but the top-line data MyoKardia Inc. unveiled Aug. 7 for its Phase II cardiomyopathy candidate mavacamten had a big impact on the biotech's stock. The company's share price soared 83% on the day and market analysts suggested there could be an opportunity for accelerated clinical development and potential breakthrough therapy designations.

MyoKardia is partnered on the drug with Sanofi, one of its initial investors via the French pharma's Sunrise open innovation initiative. Sanofi paid $45m up front ($10m an equity...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By 

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By 

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By 

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By 

New CEO Renée Aguiar-Lucander is marking her mark.

More from R&D

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By 

New CEO Renée Aguiar-Lucander is marking her mark.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

Gilead Ready To Go After Hepatitis D Again

 
• By 

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.